A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00458445
Recruitment Status : Withdrawn (This study was stopped by the sponsor before enrollment based on a non-safety related corporate decision.)
First Posted : April 10, 2007
Last Update Posted : March 5, 2015
Information provided by:

April 2, 2007
April 10, 2007
March 5, 2015
April 2007
Not Provided
Driver Safety (DS) Score averaged over 3 driving assessments at one interim and one final visit.
Same as current
Complete list of historical versions of study NCT00458445 on Archive Site
Simulated DS scores & individual components, averaged over the testing times. Interim & final visits: ADHD-RS-IV, CGI-I and Self-Rating of DS Performance Questionnaire. TEAEs, vital signs, lab parameters, physical exams & ECG measurements.
Same as current
Not Provided
Not Provided
A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators
A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether SPD465 is safe and effective in the treatment of ADHD in young adult drivers after a duration of 16 hours.
Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Attention Deficit Hyperactivity Disorder
Drug: SPD465
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  1. Subject must have a valid driver's license with a minimum of 3 years of driving experience.
  2. Subject reports daily driving activity.
  3. Subject is fluent in English.
  4. Subject must be male or non-pregnant, non-lactating female who agrees to comply with any applicable contraceptive requirements of the protocol.
  5. Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities
  6. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD) established by a comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria

Exclusion criteria:

  1. Subject is significantly underweight or morbidly obese.
  2. Subject has a controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as Post Traumatic Stress Disorder (PTSD), psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder or other symptomatic manifestations that, in the opinion of the examining Physician, will contraindicate SPD465 treatment or confound efficacy or safety assessments.
  3. Subject with a lifetime history of psychosis or bipolar disorder.
  4. Subject with any concurrent chronic or acute illness or unstable medical condition, either treated or untreated.
  5. Subject with a history of mental retardation or a severe learning disability.
  6. Subject is naïve to ADHD treatment with methylphenidate or amphetamine.
  7. Subject has a history of glaucoma or narrow angle glaucoma.
  8. Subject has a history of seizure (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of Tourette's Disorder.
  9. Subject has known cardiac structural abnormalities as well as any other condition that may affect cardiac performance.
  10. Subject has clinically significant ECG or laboratory abnormalities at Screening or Baseline.
  11. Subject has a history of hypertension or has a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg10.
  12. Subject has used any psychoactive prescription medication or over-the-counter (OTC) medication requiring more than a 28-day washout. Hormonal contraceptives are acceptable.
  13. Subject has a documented allergy, intolerance, or documented history of non-responsivity to amphetamine.
  14. Subject currently has (or had a history within the last 6 months) a substance use disorder (excluding nicotine).
  15. Subject has taken another investigational drug or taken part in a clinical trial within the last 30 days prior to Screening.
  16. Female subject is pregnant or lactating.
Sexes Eligible for Study: All
19 Years to 25 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Timothy Whitaker, M.D., Shire Pharmaceutical
Not Provided
Principal Investigator: Cynthia Huffman, M.D. Meridien Research
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP